I'm LongbridgeAI, I can summarize articles.Abbott (ABT) fell 3.68% this week to close at $108.33, against a 0.09% gain for the S&P 500, an underperformance of roughly 3.77 percentage points. The stock opened Monday at $111.54, spiked to a weekly high of $113.91, then faded across the next four sessions to a Friday low of $107.36 before settling at $108.33. Weekly amplitude was 5.87%. Average daily volume came near 7.7m shares, more than 20% below the 60-day median, so the pullback played out on relatively light turnover.
The Week
Abbott (ABT) fell 3.68% this week to close at $108.33, against a 0.09% gain for the S&P 500, an underperformance of roughly 3.77 percentage points. The stock opened Monday at $111.54, spiked to a weekly high of $113.91, then faded across the next four sessions to a Friday low of $107.36 before settling at $108.33. Weekly amplitude was 5.87%. Average daily volume came near 7.7m shares, more than 20% below the 60-day median, so the pullback played out on relatively light turnover.
Key Events
Company news this week centred on product and clinical updates. On Monday, Abbott launched the first ready-to-feed liquid infant formula made with whole milk in the U.S., priced similarly to its existing Similac powdered formula. The same day, late-breaking data for its TactiFlex Duo Ablation Catheter showed positive outcomes in complex AFib cases. On Tuesday, Mead Johnson won the Inman bellwether NEC lawsuit verdict in federal MDL. Several institutions disclosed new positions during the week, including Advisors Preferred, Callan Family Office, Ieq Capital and Ally Financial, with combined purchases in the tens of millions of dollars. On Thursday, VP and Controller John A. McCoy Jr disposed of roughly $8.7k in common shares, a routine small sale.
Analyst Ratings
Across 28 institutions covering ABT, 17 rate it buy, 4 over, 6 hold and 1 no opinion; none rate it under or sell. The consensus recommendation is buy. The consensus target sits at $120.20, about 10.96% above the latest close of $108.33. Targets range from $103 to $135, with the low end slightly below spot, reflecting some disagreement on near-term valuation. Within 142 medical-device names, Abbott ranks 7th by analyst rating.
The Week Ahead
Macro data dominate next week. Tuesday brings the NFIB small-business optimism index; Thursday is heavy with initial jobless claims, PPI prints and existing-home sales. Abbott itself has no earnings scheduled, but rate and inflation figures can shift valuation expectations across the medical-device sector. After this week’s pullback on lighter volume, the key chart level to watch is whether the $107-108 area around the weekly low holds.
In Short
Abbott’s week mixed a bullish-leaning analyst setup with weaker price action: most brokers rate it buy and the consensus target still sits above spot, yet the stock underperformed the S&P 500 while the latest session’s large-lot money turned net buyer. Valuation remains mid-to-high at roughly 34.9x P/E and 3.69x P/B. The next catalysts split into two tracks: macro data on the sector’s valuation expectations, and whether the infant-formula launch and AFib catheter data convert into orders or rating updates; on the tape, the $107.36 weekly low is the support line to follow.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.